Login / Signup

Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study.

Faustino Peron FilhoAndressa de Souza MoreiraAnna Larissa Faria JanesAlexandre Wagner Silva de Souza
Published in: RMD open (2024)
LEF and ADA had comparable outcomes after a median of 15.0 months of follow-up. However, withdrawal from therapy and mild-to-moderate adverse events were only observed in the LEF group.
Keyphrases
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • ulcerative colitis
  • stem cells
  • hidradenitis suppurativa
  • bone marrow
  • cell therapy